Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,335JPY
22 Feb 2017
Change (% chg)

-- (--)
Prev Close
¥5,335
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,291,437
52-wk High
¥5,587
52-wk Low
¥4,098

Select another date:

Mon, Feb 20 2017

BRIEF-Takeda Pharmaceutical to transfer consumer healthcare business to wholly owned unit

* Says the co plans to transfer domestic consumer healthcare business to its wholly owned unit, a Tokyo-based medical supplies firm

BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals

* Says co completes full acquisition of ARIAD Pharmaceuticals Inc on Feb. 16(U.S. local time), at $24.00 per share

BRIEF-Takeda Pharmaceutical says PRA Health Sciences and Takeda Partnership Expands to Japan

* Says PRA Health Sciences Inc and Takeda Pharmaceutical Company Limited have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan

D.C. Circuit refuses to revive Takeda appeal to block rival gout drug

A federal appeals court has refused to revive Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates' bid to block Hikma Pharmaceuticals PLC from selling its gout drug Mitigare.

Judge revives antitrust claims against Takeda over Actos

A federal appeals court on Wednesday revived claims by health plans accusing Takeda Pharmaceuticals of delaying generic versions of its blockbuster diabetes drug Actos by misrepresenting patents it had on the drug.

Takeda urges Federal Circuit to revive Velcade patent

A lawyer for Japanese drugmaker Takeda Pharmaceuticals Co on Monday urged a federal appeals court to revive a patent on its top-selling cancer drug Velcade, which faces generic competition later this year.

REFILE-Japan's Takeda committed to single-digit U.S. drug price rises

TOKYO, Feb 1 Japan's largest drugmaker, Takeda Pharmaceuticals Co, on Wednesday said it would maintain its pricing model in the U.S. market, brushing off demands by U.S. President Donald Trump for drugmakers to offer cheaper drugs.

Japan's Takeda committed to single-digit U.S. drug price rises

TOKYO Japan's largest drugmaker, Takeda Pharmaceuticals Co, on Wednesday said it would maintain its pricing model in the U.S. market, brushing off demands by U.S. President Donald Trump for drugmakers to offer cheaper drugs.

BRIEF-Takeda Pharmaceutical and Shionogi & Co to develop treatment techniques to combat Dementia- Nikkei

* Takeda Pharmaceutical and Shionogi & Co. with three other Japanese drug companies to develop treatment techniques to combat Dementia

Takeda, Hikma clash again in D.C. Circuit over gout drug

Hikma Pharmaceuticals PLC is fighting back against a bid by Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates to revive a case in a Washington, D.C. federal appeals court in order to block Hikma from selling its gout drug Mitigare.

Select another date:

More From Around the Web